Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087322 | 0.90 | TRPA1 (0.69) | TRPA1TRPV4 | |
| SCHEMBL1689557 | 0.90 | TRPA1 (0.76) | TRPA1TRPV4 | |
| SCHEMBL476114 | 0.86 | TRPA1 (0.58) | TRPA1TRPV4 | |
| SCHEMBL1689559 | 0.86 | TRPA1 (0.81) | TRPA1TRPV4 | |
| SCHEMBL1689547 | 0.86 | TRPA1 (0.73) | TRPA1TRPV4 | |
| SCHEMBL1689533 | 0.84 | TRPA1 (0.69) | TRPA1TRPV4 | |
| SCHEMBL1689579 | 0.84 | TRPA1 (0.60) | TRPA1TRPV4 | |
| SCHEMBL1803441 | 0.83 | TRPA1 (1.00) | TRPA1TRPV4 | |
| SCHEMBL1689649 | 0.83 | TRPA1 (0.70) | TRPA1TRPV4 | |
| SCHEMBL1689560 | 0.83 | TRPA1 (0.77) | TRPA1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411397-B1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | claimed |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-01-12 | — | — | US | claimed |
| US-8575178-B2 | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-8575178-B2 | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2411397-B1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-01-12 | — | — | US | disclosed |
| WO-2010109328-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | TRPA1 1/4885TRPV4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.